Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...